World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 8 March 2021
Main ID:  NCT04032158
Date of registration: 23/07/2019
Prospective Registration: Yes
Primary sponsor: EMD Serono Research & Development Institute, Inc.
Public title: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
Scientific title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Date of first enrolment: August 26, 2019
Target sample size: 3
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/show/NCT04032158
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 3
Countries of recruitment
Argentina Austria Belgium Bosnia and Herzegovina Bulgaria Canada Croatia Czechia
Estonia France Georgia Germany Hungary Israel Italy Korea, Republic of
Mexico Montenegro Poland Russian Federation Serbia Spain Taiwan Ukraine
United Kingdom United States
Contacts
Name:     Medical Responsible
Address: 
Telephone:
Email:
Affiliation:  Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Key inclusion & exclusion criteria

Inclusion Criteria: - Participants are diagnosed with RMS (relapsing-remitting multiple
sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in
accordance with 2017 Revised McDonald criteria (Thompson 2018) - Participants with one or
more documented relapses within the 2 years before Screening with either: a. one relapse
which occurred within the last year prior to randomization, OR b. the presence of at least
1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization -
Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Baseline.
Participants with an EDSS score <= 2 at Screening are only eligible for participation if
their disease duration (time since onset of symptoms) is no more than 10 years -
Participants are neurologically stable for >= 30 days prior to both screening and baseline
- Female participants must be neither pregnant nor breast-feeding and must lack
child-bearing potential, as defined by either: post-menopausal or surgically sterile or use
an effective method of contraception for the duration of the study - Participants have
given written informed consent prior to any study-related procedure - Other protocol
defined inclusion criteria could apply Exclusion Criteria: - Participants diagnosed with
Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a).
Participants with Primary Progressive MS. b). Participants with secondary progressive MS
without evidence of relapse.

- Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 at
screening.

- Immunologic disorder other than MS, or any other condition requiring oral, intravenous
(IV) , intramuscular, or intra-articular corticosteroid therapy, with the exception of
well-controlled Type 2 diabetes mellitus or well controlled thyroid disease.

- Other protocol defined exclusion criteria could apply.



Age minimum: 18 Years
Age maximum: 55 Years
Gender: All
Health Condition(s) or Problem(s) studied
Relapsing-remitting Multiple Sclerosis
Intervention(s)
Drug: Avonex®
Drug: Placebo
Drug: Evobrutinib
Primary Outcome(s)
Annualized Relapse Rate (ARR) [Time Frame: At Week 96]
Secondary Outcome(s)
Absolute Concentrations of Immunoglobulin (Ig) Levels [Time Frame: Baseline up to Week 100]
Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs) [Time Frame: Baseline up to Week 100]
Total Number of New or Enlarging T2 Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans [Time Frame: At Weeks 24, 48, and 96]
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Fatigue Short Form Score [Time Frame: Baseline, Week 96]
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) MS Physical Function (PF) Short Form Score [Time Frame: Baseline, Week 96]
Total Number of Gadolinium-Enhancing (Gd+) T1 Lesions Assessed by Magnetic Resonance Imaging (MRI) Scans [Time Frame: At Weeks 24, 48, and 96]
Time to First Occurrence of 12-Week Confirmed Expanded Disability Status Scale (EDSS) Progression [Time Frame: Baseline up to 96 weeks]
Change From Baseline in Immunoglobulin (Ig) Levels [Time Frame: Baseline up to Week 100]
Time to First Occurrence of 24-Week Confirmed Expanded Disability Status Scale (EDSS) Progression [Time Frame: Baseline up to 96 weeks]
Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings [Time Frame: Baseline up to Week 100]
Secondary ID(s)
MS200527_0073
2018-004701-11
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Merck KGaA, Darmstadt, Germany
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history